+ All News

1 ^th June 2022 - More information Call for general extraordinary shareholders’ meeting of the company highlight therapeutics, S.L. June 27, 2022, at 12:30

13 ^th April 2022 - More information Highlight Therapeutics announces follow-up results from Phase 2b study of BO-112 + anti-PD1 in confirmed anti-PD1 progressor melanoma patients at AACR

15 ^th March 2022 - More information Highlight Therapeutics to present at the American Association for Cancer Research (AACR) Annual Meeting 2022

2 ^th December 2021 - More information Highlight Therapeutics & Cima announce positive results from pre-clinical study combining BO112 + STING agonist published in Journal for ImmunoTherapy of Cancer

12 ^th November 2021 - More information Highlight announces positive preliminary results from Phase 2b study of BO-112+anti-PD1 in confirmed anti-PD1 progressor melanoma patients at SITC

14 ^th April 2021 - More information Highlight to present data from Phase 2 immunotherapy studies of liver metastases and melanoma data

15 ^th April 2021 - More information Call for general extraordinary shareholders’ meeting of the company highlight therapeutics, S.L. April 30th, 2021, at 11:00

2 ^nd March 2021 - More information Highlight Therapeutics and Pivotal work together on Melanoma therapy and launch a Phase IIa trial to examine BO-112 efficacy and safety

15 ^th September 2020 - More information Call for general extraordinary shareholders’ meeting of the company highlight therapeutics, S.L. October 1, 2020, at 11:00

2 ^nd September 2020 - More information Second collaboration with MSD to evaluate combination of BO-112 and KEYTRUDA®

26 ^th June 2020 - More information Highlight Therapeutics announces first patient dosed in Phase IIa study in liver metastasis

9 ^th June 2020 - More information Call for general ordinary shareholders’ meeting of the company highlight therapeutics, S.L. June 25, 2020, at 12:00

17 ^th April 2020 - Download PDF Highlight Therapeutics strengthens Board and Advisory Board

17 ^th April 2020 - Download PDF Highlight Therapeutics announces name change from Bioncotech and launch of new website

17 ^th April 2020 - View online Highlight Therapeutics commentary published in the European Biotechnology magazine

2 ^nd April 2020 - Download PDF Highlight Therapeutics published in the European Biopharmaceutical Review

28 ^th February 2020 - Download PDF Highlight Therapeutics selected for Cancer Research UK project

12 ^th December 2019 - Download PDF Phase I BO-112 Data Presented at ESMO Immuno-Oncology Congress 2019

10 ^th December 2019 - Download PDF Oncology Clinical Trial Collaboration with MSD